Seaport Therapeutics, Inc. IPO - What You Need to Know

Thinking about the Seaport Therapeutics IPO? It is exciting to get in on the ground floor of a biotech company, but these investments can be a rollercoaster. Here is a plain-English breakdown of what you need to know before you invest.

1. What does this company do?

Seaport Therapeutics develops medicines for brain and mental health conditions. Their "secret sauce" is the Glyph platform. It uses the body’s natural lymphatic system to help drugs get absorbed better. By attaching a drug to a fat molecule, the platform helps the medicine bypass the liver. This allows more of the drug to reach the brain while reducing the side effects often caused by high doses.

2. What is in their "medicine cabinet"?

They have three main programs using the Glyph platform:

• GlyphAllo (SPT-300): A treatment for Major Depressive Disorder. They are currently running a mid-stage clinical trial. They expect results in the first half of 2027.
• GlyphAgo (SPT-320): A treatment for Generalized Anxiety Disorder. Early data shows the Glyph platform helps the drug avoid liver issues and improves how well the body absorbs it.
• Glyph2BLSD: An early-stage program for conditions like treatment-resistant depression and PTSD. It aims to improve how the body processes powerful drugs that were previously difficult to use.

3. How do they make money?

Seaport does not make money yet. They have not sold any products and have lost about $145 million so far. This is normal for a company spending heavily on research and clinical trials. Last year, they spent $82 million on research and development. Because they are an "emerging growth company," they have fewer reporting requirements than larger, established firms. They will need to raise more money from investors until they have a product on the market.

4. Who is running the show?

CEO Daphne Zohar is a serial entrepreneur who founded PureTech Health. The leadership team includes the co-founders of Karuna Therapeutics. Karuna successfully developed a schizophrenia drug and was bought by Bristol Myers Squibb for $14 billion in 2024. While this team has a strong track record, Seaport is a separate company with its own unique risks.

5. What are the main risks?

Biotech is high-risk. Beyond the chance that a drug might fail, consider these risks:

• The "Unproven" Factor: The Glyph platform is new. If it does not work better than existing treatments in human trials, the company’s value could drop significantly.
• Trial Uncertainty: The FDA might demand extra, expensive, and time-consuming trials. This could delay market entry by years.
• Reliance on Others: Seaport licenses its core technology from Monash University. If they lose this agreement or have legal disputes, they lose their main technology.
• Competition: Large pharmaceutical companies with massive budgets are also working on these conditions. If they release better drugs, Seaport may struggle to compete.

6. How to decide if this is for you

Investing in a biotech company that isn't making money yet is a bet on science. Before you buy in, ask yourself:

• Is this money I can afford to lose? Biotech stocks are notoriously volatile.
• Am I in it for the long haul? Clinical trials take years. This is not a "get rich quick" play.
• Do I believe in the tech? Your investment is essentially a vote of confidence in the Glyph platform’s ability to change how we treat mental health.

Disclaimer: I am an AI, not a financial advisor. IPOs are volatile. Always read the company’s official prospectus on the SEC website before investing.